GeneQuine on Expert Panel Discussion at Merck’s Advance Biotech Grant Program Award Ceremony, 31 January 2019, Darmstadt [ 29 Jan 2019 ]

As a previous winner of Mercks’s European Emerging Biotech Grant Program, GeneQuine’s CEO Kilian Guse will hold an introductory speech on how the grant accelerated GeneQuine's development of a novel gene therapy platform and supported the lead program in osteoarthritis.